Liminatus Pharma, Inc. Class A Common Stock (LIMN) — Tangible Net Worth Ratio
Liminatus Pharma, Inc. Class A Common Stock (LIMN) has a Tangible Net Worth Ratio of 100.0% as of March 2025. This metric is calculated by deducting intangible assets ($0.00) from net assets ($2.83 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Also explore LIMN shareholders equity momentum to track the company's year-over-year net asset growth rate.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Liminatus Pharma, Inc. Class A Common Stock Tangible Net Worth Ratio (2021–2022)
This chart shows how Liminatus Pharma, Inc. Class A Common Stock's Tangible Net Worth Ratio has changed across 2 annual periods from 2021 to 2022. As of March 2025, the ratio stands at 100.0%, reflecting net assets of $2.83 Million with intangible assets of $0.00 USD. For live market cap and overall valuation, see how much is Liminatus Pharma, Inc. Class A Common St worth.
Annual Tangible Net Worth Ratio for Liminatus Pharma, Inc. Class A Common Stock (2021–2022)
The table below presents the year-by-year Tangible Net Worth Ratio for Liminatus Pharma, Inc. Class A Common Stock from 2021 to 2022, covering 2 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. See how financially flexible is Liminatus Pharma, Inc. Class A Common St to measure the company's free cash flow as a share of total liabilities.
| Year | Tangible NW Ratio | Net Assets (USD) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2022 | 100.0% | $1.29 Million | $0.00 | $15.49 Million | ▲ +0.0 pp |
| 2021 | 100.0% | $254.87 Million | $0.00 | $276.44 Million | — |